Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 3, 2017 (10 years ago)

CycloSPORINE Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradations Specifications; out of specification results for Maximum Unknown Impurities and Total Impurities.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

CycloSPORINE Capsules, USP, 100 mg, 30 count bottle, Rx Only, Manufactured by Apotex, Inc., Toronto, Ontario, Canada, Manufactured for Apotex Corp., Weston, FL --- NDC 60505-0134-0

Affected NDC 60505-0134-00

Compare with the code on your package — it is the most precise check available.

Drug: Cyclosporine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cyclosporine
NDC 60505-0134
100 mg/1 Capsule, Gelatin Coated
Oral
Apotex Corp. Rx
Recalling firm
Apotex Inc.
NDC code
60505-0134-0
Origin
N/A, Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0475-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cyclosporine recalls

See all
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

Ongoing Failed specification Novartis Pharmaceuticals Corp. NDC 0078-0110-22 D-1174-2023

Other recalls by Apotex Inc.

All 2017 recalls
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026